• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4597351)   Today's Articles (5541)   Subscriber (49348)
For: Mason AR, Drummond MF. Public funding of new cancer drugs: Is NICE getting nastier? Eur J Cancer 2009;45:1188-1192. [DOI: 10.1016/j.ejca.2008.11.040] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2008] [Revised: 11/25/2008] [Accepted: 11/26/2008] [Indexed: 11/28/2022]
Number Cited by Other Article(s)
1
Charlton V. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies. HEALTH ECONOMICS, POLICY, AND LAW 2022;17:444-470. [PMID: 35293306 DOI: 10.1017/s1744133122000032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
2
The value of anticancer drugs - a regulatory view. Nat Rev Clin Oncol 2022;19:207-215. [PMID: 34873312 DOI: 10.1038/s41571-021-00584-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2021] [Indexed: 12/18/2022]
3
Khushalani JS, Song S, Calhoun BH, Puddy RW, Kucik JE. Preventing Leading Causes of Death: Systematic Review of Cost-Utility Literature. Am J Prev Med 2022;62:275-284. [PMID: 34736801 DOI: 10.1016/j.amepre.2021.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 07/21/2021] [Accepted: 07/28/2021] [Indexed: 11/29/2022]
4
Rodriguez Santana I, Aragón MJ, Rice N, Mason AR. Trends in and drivers of healthcare expenditure in the English NHS: a retrospective analysis. HEALTH ECONOMICS REVIEW 2020;10:20. [PMID: 32607791 PMCID: PMC7325682 DOI: 10.1186/s13561-020-00278-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Accepted: 06/23/2020] [Indexed: 06/11/2023]
5
Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study. HEALTH ECONOMICS POLICY AND LAW 2019;15:386-402. [PMID: 31488229 DOI: 10.1017/s1744133119000239] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
6
Schaefer R, Schlander M. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany? Expert Rev Pharmacoecon Outcomes Res 2018;19:453-462. [PMID: 30556745 DOI: 10.1080/14737167.2019.1559732] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
7
Maynou L, Cairns J. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. Health Policy 2018;123:130-139. [PMID: 30477736 DOI: 10.1016/j.healthpol.2018.11.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 10/24/2018] [Accepted: 11/05/2018] [Indexed: 11/26/2022]
8
Angeles A, Hung W, Cheung WY. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. Med Oncol 2018;35:114. [PMID: 29936654 DOI: 10.1007/s12032-018-1176-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Accepted: 06/20/2018] [Indexed: 12/11/2022]
9
Khalili H, Sameti A. Healthcare quality and medicine reimbursement criteria in Iran. INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING 2017. [DOI: 10.1108/ijphm-06-2016-0032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
10
Jayasundara K, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. PHARMACOECONOMICS - OPEN 2017;1:167-173. [PMID: 29441496 PMCID: PMC5691840 DOI: 10.1007/s41669-017-0022-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
11
Karikios DJ, Chim L, Martin A, Nagrial A, Howard K, Salkeld G, Stockler MR. Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia. Intern Med J 2017;47:400-407. [DOI: 10.1111/imj.13350] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2016] [Revised: 11/21/2016] [Accepted: 11/28/2016] [Indexed: 11/30/2022]
12
MacLeod TE, Harris AH, Mahal A. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 2017;9:201-22. [PMID: 26370257 DOI: 10.1007/s40271-015-0139-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
13
Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. Hepatology 2016;64:1331-42. [PMID: 26926906 DOI: 10.1002/hep.28527] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 02/18/2016] [Accepted: 02/21/2016] [Indexed: 12/11/2022]
14
Leigh S, Granby P. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2016;19:567-576. [PMID: 27565274 DOI: 10.1016/j.jval.2016.02.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Revised: 01/21/2016] [Accepted: 02/19/2016] [Indexed: 06/06/2023]
15
Schilling C, Mortimer D, Dalziel K. Using CART to Identify Thresholds and Hierarchies in the Determinants of Funding Decisions. Med Decis Making 2016;37:173-182. [PMID: 27005520 DOI: 10.1177/0272989x16638846] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
16
Winn AN, Ekwueme DU, Guy GP, Neumann PJ. Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review. Am J Prev Med 2016;50:241-8. [PMID: 26470806 PMCID: PMC5846573 DOI: 10.1016/j.amepre.2015.08.009] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 07/27/2015] [Accepted: 08/04/2015] [Indexed: 02/05/2023]
17
Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015;19:1-503, v-vi. [PMID: 25692211 DOI: 10.3310/hta19140] [Citation(s) in RCA: 475] [Impact Index Per Article: 52.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]  Open
18
Dakin H, Devlin N, Feng Y, Rice N, O'Neill P, Parkin D. The Influence of Cost-Effectiveness and Other Factors on Nice Decisions. HEALTH ECONOMICS 2015;24:1256-1271. [PMID: 25251336 DOI: 10.1002/hec.3086] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2013] [Revised: 05/01/2014] [Accepted: 06/20/2014] [Indexed: 05/03/2023]
19
Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT 2015. [DOI: 10.5301/grhta.5000206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
20
Cerri KH, Knapp M, Fernandez JL. Untangling the Complexity of Funding Recommendations: A Comparative Analysis of Health Technology Assessment Outcomes in Four European Countries. Pharmaceut Med 2015. [DOI: 10.1007/s40290-015-0112-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
21
Barriers to access and use of high cost medicines: A review. HEALTH POLICY AND TECHNOLOGY 2015. [DOI: 10.1016/j.hlpt.2015.04.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
22
McGuire A, Drummond M, Martin M, Justo N. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes? Expert Rev Pharmacoecon Outcomes Res 2015;15:599-605. [DOI: 10.1586/14737167.2015.1039518] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
23
Pujolras LM, Cairns J. Why do some countries approve a cancer drug and others don’t? J Cancer Policy 2015. [DOI: 10.1016/j.jcpo.2015.05.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
24
Stevens W, Philipson TJ, Khan ZM, MacEwan JP, Linthicum MT, Goldman DP. Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007. Health Aff (Millwood) 2015;34:562-70. [PMID: 25847637 DOI: 10.1377/hlthaff.2014.0634] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
25
Saret CJ, Winn AN, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 2015;125:1866-9. [PMID: 25655601 PMCID: PMC4366623 DOI: 10.1182/blood-2014-07-592832] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 12/15/2014] [Indexed: 01/05/2023]  Open
26
McDonald H, Charles C, Elit L, Gafni A. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes? PHARMACOECONOMICS 2015;33:235-241. [PMID: 25424496 DOI: 10.1007/s40273-014-0238-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
27
Fischer KE, Stargardt T. Early Benefit Assessment of Pharmaceuticals in Germany. Med Decis Making 2014;34:1030-47. [DOI: 10.1177/0272989x14546377] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
28
Nakahara N, Kamae I. Regression analysis of indicating multiple incremental cost-effectiveness ratios for non-small cell lung cancer treatment. J Med Econ 2014;17:547-54. [PMID: 24826807 DOI: 10.3111/13696998.2014.923890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
29
Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. J Cancer Policy 2014. [DOI: 10.1016/j.jcpo.2014.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
30
Bonastre J, Chevalier J, Van der Laan C, Delibes M, De Pouvourville G. Access to innovation: Is there a difference in the use of expensive anticancer drugs between French hospitals? Health Policy 2014;116:162-9. [PMID: 24314625 DOI: 10.1016/j.healthpol.2013.11.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2013] [Revised: 11/01/2013] [Accepted: 11/11/2013] [Indexed: 10/26/2022]
31
Peppercorn J, Zafar SY, Houck K, Ubel P, Meropol NJ. Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol 2014;15:e132-8. [PMID: 24534292 DOI: 10.1016/s1470-2045(13)70597-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
32
Greenberg D, Neumann PJ. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? Expert Rev Pharmacoecon Outcomes Res 2014;11:113-9. [DOI: 10.1586/erp.11.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
33
Greenberg D, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care. Isr J Health Policy Res 2013;2:44. [PMID: 24245811 PMCID: PMC3843539 DOI: 10.1186/2045-4015-2-44] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 10/01/2013] [Indexed: 11/13/2022]  Open
34
Decision making by NICE: examining the influences of evidence, process and context. HEALTH ECONOMICS POLICY AND LAW 2013;9:119-41. [DOI: 10.1017/s1744133113000030] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
35
Fischer KE, Rogowski WH, Leidl R, Stollenwerk B. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis. Health Policy 2013;112:187-96. [PMID: 23664301 DOI: 10.1016/j.healthpol.2013.04.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2012] [Revised: 02/28/2013] [Accepted: 04/16/2013] [Indexed: 10/26/2022]
36
Wild C, Nachtnebel A. [HTA-Perspective: Challenges in the early assessment of new oncological drugs]. ZEITSCHRIFT FUR EVIDENZ, FORTBILDUNG UND QUALITAT IM GESUNDHEITSWESEN 2013;107:129-135. [PMID: 23663907 DOI: 10.1016/j.zefq.2013.02.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
37
Ramjeesingh R, Meyer RM, Brouwers M, Chen BE, Booth CM. Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario. Curr Oncol 2013;20:e21-33. [PMID: 23444033 DOI: 10.3747/co.20.1166] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]  Open
38
Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2012;15:1162-71. [PMID: 23244820 DOI: 10.1016/j.jval.2012.05.006] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Revised: 05/10/2012] [Accepted: 05/11/2012] [Indexed: 05/22/2023]
39
Fischer KE. A systematic review of coverage decision-making on health technologies-evidence from the real world. Health Policy 2012;107:218-30. [PMID: 22867939 DOI: 10.1016/j.healthpol.2012.07.005] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 05/30/2012] [Accepted: 07/09/2012] [Indexed: 11/24/2022]
40
Stafinski T, Menon D, Marshall D, Caulfield T. Societal values in the allocation of healthcare resources: is it all about the health gain? PATIENT-PATIENT CENTERED OUTCOMES RESEARCH 2012;4:207-25. [PMID: 21815706 DOI: 10.2165/11588880-000000000-00000] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
41
Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur J Clin Pharmacol 2011;68:505-12. [PMID: 22166932 DOI: 10.1007/s00228-011-1173-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2011] [Accepted: 11/15/2011] [Indexed: 01/08/2023]
42
Stafinski T, Menon D, Philippon DJ, McCabe C. Health technology funding decision-making processes around the world: the same, yet different. PHARMACOECONOMICS 2011;29:475-95. [PMID: 21568357 DOI: 10.2165/11586420-000000000-00000] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
43
The future of national health systems. Br J Gen Pract 2011;61:319-20. [PMID: 21619756 DOI: 10.3399/bjgp11x572292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]  Open
44
Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Med Decis Making 2010;31:380-5. [PMID: 21088130 DOI: 10.1177/0272989x10385847] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
45
Cohen J, Looney W. What is the value of oncology medicines? Nat Biotechnol 2010;28:1160-3. [DOI: 10.1038/nbt1110-1160] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
46
Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric? J Clin Oncol 2010;28:3234-8. [DOI: 10.1200/jco.2009.26.2758] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
47
Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-8. [PMID: 20056956 DOI: 10.1093/jnci/djp472] [Citation(s) in RCA: 134] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]  Open
48
Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists. Health Aff (Millwood) 2010;29:196-202. [DOI: 10.1377/hlthaff.2009.0077] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA